Zimmer Biomet Holdings Appoints New Medical Advisors to Boost Innovation in Orthopaedics
- Zimmer Biomet appointed Dr. Jonathan M. Vigdorchik and Dr. Anand M. Murthi as new medical advisors to enhance innovation.
- Dr. Vigdorchik will guide product development and medical education initiatives in hip and knee replacements for Zimmer Biomet.
- Dr. Murthi will advise on technology development, supporting Zimmer Biomet's strategic vision in musculoskeletal care advancements.
Zimmer Biomet Strengthens Leadership with New Medical Advisors to Propel Innovation in Orthopaedics
Zimmer Biomet Holdings, Inc., a global leader in medical technology, enhances its leadership team by appointing two renowned physicians to pivotal roles within the company. Dr. Jonathan M. Vigdorchik takes on the position of Chief Medical Technology Advisor for Adult Reconstruction and Hip Implants, while Dr. Anand M. Murthi assumes the role of Chief Medical Advisor for Shoulder, Sports, Extremities, and Trauma (S.E.T.). Both appointments underscore Zimmer Biomet's commitment to advancing clinical collaboration and driving innovation in the orthopaedic sector, aligning with the company's mission to improve patient mobility and health.
Dr. Vigdorchik, an established fellowship-trained orthopaedic surgeon at the Hospital for Special Surgery in New York, brings a wealth of expertise in hip and knee replacements. His leadership experience includes serving as Division Chief of Adult Reconstruction and Joint Replacement and an academic role as an Associate Professor at Weill Cornell Medical College. In his new position, he will guide Zimmer Biomet’s product pipeline while enhancing medical education initiatives, ensuring that the company remains at the forefront of surgical advancements and patient care.
Similarly, Dr. Murthi, who is the Chief of Shoulder and Elbow Surgery at MedStar Union Memorial Hospital in Baltimore, will play a crucial role in advising on technology development within the company. His experience in directing the Shoulder and Elbow Fellowship Program and his extensive clinical background provide a strong foundation for his contributions to Zimmer Biomet’s strategic vision. Ivan Tornos, the company’s Chairman, President, and CEO, emphasizes that these appointments are integral to redefining the future of musculoskeletal care and enhancing engagement with the surgical community.
In addition to these leadership changes, Zimmer Biomet recently announced a quarterly cash dividend of $0.24 per share for the third quarter of 2025, scheduled for distribution on October 31, 2025, to shareholders on record by September 30, 2025. This financial commitment reflects the company's dedication to shareholder value while continuing to invest in innovative technologies and solutions that enhance patient care.
Zimmer Biomet’s global operations span over 25 countries, with sales in more than 100 countries, showcasing its expansive reach and influence in the medical technology field. The company maintains a progressive corporate culture, focusing on quality solutions and continuous improvement in patient experiences. Stakeholders can gain further insights into the company’s offerings and career opportunities through its official website and social media channels.
